Similarly, 177Lu-PSMA-617, a therapeutic agent targeting prostate-specific membrane antigens (PSMA), has been approved for treating recurrent or refractory metastatic prostate cancer (81). Here, FOLH1 is linked to metastatic prostate carcinoma.